Importance of this research is clearly evident as a novel monomeric peptide triagonist acting on GLP-1, GIP, and GCG receptors (174) has been found to be the most effective among existing pharmacological agonists/strategies in reversing obesity in mice (207, 208). Here, GLP1R is linked to obesity disorder.